| Overview |
| bsm-61821r-pe-cy5-100ul |
| RING2 Recombinant Monoclonal Antibody, PE-Cy5 Conjugated |
| WB, FCM |
| Human, Mouse, Rat |
| Specifications |
| PE-Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human RING2 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 6045 |
| Q99496 |
| Nucleus |
| BAP1; DING; BAP-1; HIPI3; RING2; RING1B. |
| Acts as the main E3 ubiquitin ligase on histone H2A of the PRC1 complex, while RING1 may rather act as a modulator of RNF2/RING2 activity (Probable). Association with the chromosomal DNA is cell-cycle dependent. In resting B- and T-lymphocytes, interaction with AURKB leads to block its activity, thereby maintaining transcription in resting lymphocytes.Also acts as a negative regulator of autophagy by mediating ubiquitination of AMBRA1, leading to its subsequent degradation. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz